Show simple item record

dc.contributor.authorTiseo, M.
dc.contributor.authorPopat, S.
dc.contributor.authorKim, H. R.
dc.contributor.authorAhn, M. J.
dc.contributor.authorYang, J. C.
dc.contributor.authorHan, J. Y.
dc.contributor.authorHochmair, M. J.
dc.contributor.authorLee, K. H.
dc.contributor.authorDelmonte, A.
dc.contributor.authorCampelo, M. R. G.
dc.contributor.authorKim, D. W.
dc.contributor.authorGriesinger, F.
dc.contributor.authorFelip, E.
dc.contributor.authorCalifano, Raffaele
dc.contributor.authorSpira, A. I.
dc.contributor.authorGettinger, S. N.
dc.contributor.authorLin, H. M.
dc.contributor.authorLiu, Y.
dc.contributor.authorVranceanu, F.
dc.contributor.authorCamidge, R.
dc.date.accessioned2022-04-28T13:57:37Z
dc.date.available2022-04-28T13:57:37Z
dc.date.issued2022en
dc.identifier.citationTiseo M, Popat S, Kim HR, Ahn M-J, Yang JC, Han J-Y, et al. 29P Brigatinib (BRG) vs crizotinib (CRZ) in anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor-naive ALK+ non-small cell lung cancer (NSCLC): ALTA-1L final results. Vol. 33, Annals of Oncology. Elsevier BV; 2022. p. S44–5.en
dc.identifier.doi10.1016/j.annonc.2022.02.038en
dc.identifier.urihttp://hdl.handle.net/10541/625141
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.annonc.2022.02.038en
dc.titleBrigatinib (BRG) vs crizotinib (CRZ) in anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor-naive ALK plus non-small cell lung cancer (NSCLC): ALTA-1L final resultsen
dc.typeMeetings and Proceedingsen
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]
refterms.dateFOA2022-06-28T09:38:07Z


Files in this item

Thumbnail
Name:
TiseoM.pdf
Size:
144.1Kb
Format:
PDF
Description:
Identified with Open Access button

This item appears in the following Collection(s)

Show simple item record